Current pharmacological interventions for nvAMD, PDR/DME and ROP target the VEGF signaling pathway with IVT injections of bevacizumab, ranibizumab, pegaptanib, aflibercept and brolucizumab [100]. This evidence concerns the gene VEGFA and retinopathy of prematurity.